Journal List > Korean J Lab Med > v.27(4) > 1011410

TOOLS
Lee, Kim, Roh, Lee, Yum, Yong, Lee, and Chong: In Vitro Activity of Arbekacin Against Clinical Isolates of Staphylococcus species and Gram-negative Bacilli
Original Article

Korean J Leg Med 2007;27(4):292-297.

Published online: 10 February 2007

DOI: https://doi.org/10.3343/kjlm.2007.27.4.292

In Vitro Activity of Arbekacin Against Clinical Isolates of Staphylococcus species and Gram-negative Bacilli

Jonghan Lee, M.D.1, 2, Chang Ki Kim, M.D.1, 2, Kyoung Ho Roh, M.D.3, Hyukmin Lee, M.D.4, Jong Hwa Yum, M.D.2, Dongeun Yong, M.D.1, 2, Kyungwon Lee, M.D.1, 2, Yunsop Chong, M.D.1, 2

1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea

2Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea

3Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea

4Department of Laboratory Medicine, Kwandong University College of Medicine, Goyang, Korea

Received 12 May 2007       Revised 13 June 2007       Accepted 13 June 2007

Copyright © 2007 The Korean Society for Legal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Methicillin-resistant Staphylococcus aureus (MRSA) and some gram-negative bacilli are very prevalent nosocomial pathogens, commonly causing mixed infections, and are often resistant to multiple drugs. Arbekacin is an aminoglycoside used for the treatment of MRSA infections, but is also active against some gram-negative bacilli. The aim of this study was to determine in vitro activity of arbekacin against recent clinical isolates of staphylococci and gram-negative bacilli.

Materials and Methods

The strains were isolated from clinical specimens of patients at Severance Hospital in 2003. Antimicrobial susceptibility was tested by the Clinical and Laboratory Standards Institute agar dilution method. The following arbekacin breakpoints were used: susceptible, ≤4 μg/mL; and resistant, ≥16 μg/mL.

Results

All isolates of staphylococci tested were inhibited by ≤4 μg/mL of arbekacin, regardless of their methicillin susceptibility. The MIC90s of arbekacin, 1–4 μg/mL, were 8->32-fold and >32–128-fold lower than those of amikacin and gentamicin, respectively. The resistance rates of MRSA, methicillin-susceptible S. aureus, methicillin-resistant coagulase-negative staphylococci (CNS) and methicillin-susceptible CNS were 0% to arbekacin, 0–54% to amikacin, and 24–79% to gentamicin. The MIC90s of arbekacin for Escherichia coli and Citrobacter freundii, 1 μg/mL and 16 μg/mL, were 2–4-fold and 8–16-fold lower than those of amikacin and gentamicin, respectively. However, The MIC90s of arbekacin for other species of gram-negative bacilli, 64->128 μg/mL, were similar to those of other aminoglycosides.

Conclusions

Arbekacin may be a useful alternative to glycopeptides for the treatment of monomicrobial methicillin-resistant staphylococcal infections, as well as mixed infections with gram-negative bacilli, as most isolates of E. coli, C. freundii and some other gram-negative bacilli were also susceptible to arbekacin.

Keywords: Arbekacin, MRSA, Gram-negative bacilli, In vitro activity

References

1. Chambers HF. Methicillin-resistant staphylococci. Clin Microbiol Rev. 1988; 1:173–86.
crossref
2. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect. 2005; 11(S):):S22–8.
crossref
3. Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect. 2005; 11:33–42.
4. Wie SH, Kang JH, Huh DH, Lee DG, Kim SI, Kim YR, et al. Antimicrobial activities of arbekacin against clinical isolates of Staphylococcus aureus and coagulase-negative Staphylococcus species. Korean J Infect Dis. 2001; 33:254–60.
5. Drinka P, Faulks JT, Gauerke C, Goodman B, Stemper M, Reed K. Adverse events associated with methicillin-resistant Staphylococcus aureus in a nursing home. Arch Intern Med. 2001; 161:2371–7.
6. Shankar EM, Mohan V, Premalatha G, Srinivasan RS, Usha AR. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med. 2005; 16:567–70.
crossref
7. Zahar JR, Clec'h C, Tafflet M, Garrouste-Orgeas M, Jamali S, Mourvillier B, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis. 2005; 41:1224–31.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Seventeenth informational supplement. M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute;2007.
9. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999; 43:727–37.
crossref
10. Azucena E, Mobashery S. Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist Updat. 2001; 4:106–17.
crossref
11. Ferretti JJ, Gilmore KS, Courvalin P. Nucleotide sequence analysis of the gene specifying the bifunctional 6′-aminoglycoside acetyl-transferase 2″-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities. J Bacteriol. 1986; 167:631–8.
12. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993; 57:138–63.
crossref
13. Schmitz FJ, Fluit AC, Gondolf M, Beyrau R, Lindenlauf E, Verhoef J, et al. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. J Antimicrob Chemother. 1999; 43:253–9.
crossref
14. Ida T, Okamoto R, Shimauchi C, Okubo T, Kuga A, Inoue M. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. J Clin Microbiol. 2001; 39:3115–21.
15. Obayashi Y, Fujita J, Ichiyama S, Hojo S, Negayama K, Takashima C, et al. Investigation of nosocomial infection caused by arbekacin-resistant, methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 1997; 28:53–9.
16. Ishino K, Ishikawa J, Ikeda Y, Hotta K. Characterization of a bifunctional aminoglycoside-modifying enzyme with novel substrate specificity and its gene from a clinical isolate of methicillin-resistant Staphylococcus aureus with high arbekacin resistance. J Antibiot (Tokyo). 2004; 57:679–86.
17. Cordeiro JC, Reis AO, Miranda EA, Sader HS. In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillinresistant Staphylococcus aureus isolated in Brazilian hospitals. Braz J Infect Dis. 2001; 5:130–5.
crossref
18. Matsuo H, Kobayashi M, Kumagai T, Kuwabara M, Sugiyama M. Molecular mechanism for the enhancement of arbekacin resistance in a methicillin-resistant Staphylococcus aureus. FEBS Lett. 2003; 546:401–6.
19. Chong Y, Lee K, Shin JW, Shin HB, Lim JB. Activities of arbekacin against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Korean J Chemother. 1997; 15:319–28.
20. Lee SM, Song EJ, Yang EK, Bae IK, Jeong SH, Kim JM, et al. Antimicrobial activities of arbekacin against recent isolates of Staphylococcus aureus in Korean hospitals. Korean J Clin Microbiol. 2006; 9:13–7.
21. Lee JY, Oh WS, Ko KS, Heo ST, Moon CS, Ki HK, et al. Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus. J Korean Med Sci. 2006; 21:188–92.
22. Kim TH, Choo EJ, Lee MS, Kim NJ, Woo JH, Ryu JS, et al. Clinical efficacy and safety with arbekacin for methicillin-resistant Staphylococcus aureus (MRSA) infections. Korean J Med. 2003; 65:239–44.
23. Deguchi K, Suzuki Y, Ishihara R, Ishii Y, Nakazawa A, Matsumoto Y, et al. Antimicrobial activities of arbekacin against methicillin-resistant Staphylococcus aureus. Jpn J Antibiot. 1997; 50:1–11.
24. Ishino K, Ishikawa J, Ikeda Y, Hotta K. Characterization of a bifunctional aminoglycoside-modifying enzyme with novel substrate specificity and its gene from a clinical isolate of methicillin-resistant Staphylococcus aureus with high arbekacin resistance. J Antibiot (Tokyo). 2004; 57:679–86.
25. Choi SM, Kim SH, Kim HJ, Lee DG, Choi JH, Yoo JH, et al. Multiplex PCR for the detection of genes encoding aminoglycoside modifying enzymes and methicillin resistance among Staphylococcus species. J Korean Med Sci. 2003; 18:631–6.
26. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis. 1997; 24:46–62.
27. Park YJ, Lee S, Yu JK, Woo GJ, Lee K, Arakawa Y. Co-production of 16S rRNA methylases and extended-spectrum beta-lactamases in AmpC-producing Enterobacter cloacae, Citrobacter freundii and Serratia marcescens in Korea. J Antimicrob Chemother. 2006; 58:907–8.

Table 1.
Activities of antimicrobial agents against Staphylococcus species
Organism (N tested) Antimicrobial agent* MIC (μg/mL)
 Susceptibility (%)
Range 50% 90% S I R
Methicillin-resistant Oxacillin 32->128 >128 >128 0 −† 100
S. aureus Vancomycin 0.5–2 1 1 100 0 0
(52) Amikacin 4->128 64 >128 39 8 54
  Gentamicin 0.25->128 64 >128 21 0 79
  Arbekacin 0.5–4 1 4 100 0 0
Methicillin-susceptible Oxacillin 0.06–1 0.5 0.5 100 − 0
S. aureus Vancomycin 0.5–1 0.5 1 100 0 0
(33) Amikacin 0.5–32 2 8 97 3 0
  Gentamicin 0.06->128 0.5 128 73 3 24
  Arbekacin 0.06–2 0.5 1 100 0 0
Methicillin-resistant CNS Oxacillin 0.5->128 4 64 0 − 100
(26) Vancomycin 0.25–2 1 2 100 0 0
  Amikacin 0.12–64 2 32 81 12 8
  Gentamicin 0.06–128 16 64 27 15 58
  Arbekacin 0.06–2 0.25 1 100 0 0
Methicillin-susceptible CNS Oxacillin 0.06–0.25 0.12 0.25 100 − 0
(29) Vancomycin 0.5–2 1 2 100 0 0
  Amikacin 0.5–16 1 8 100 0 0
  Gentamicin 0.06–128 0.12 128 69 7 24
  Arbekacin 0.06–2 0.12 1 100 0 0

* Arbekacin breakpoint was applied as susceptible, ≤4 μg/mL; intermediate, 8 μg/mL; resistant, ≥16 μg/mL.

† Not applicable. Abbreviations: MIC, Minimum inhibitory concentration; CNS, coagulase-negative staphylococci.

Table 2.
Activities of antimicrobial agents against gram-negative bacilli
Organism (N tested) Antimicrobial agent* MIC (μg/mL)
 Susceptibility (%)
Range 50% 90% S I R
E. coli Cefotaxime ≤0.03–128 0.06 0.25 93 0 7
(30) Gentamicin ≤0.12–64 0.5 16 87 0 13
  Amikacin 0.5–32 2 4 97 3 0
  Arbekacin 0.25–16 1 1 93 0 7
  Ciprofloxacin ≤0.03–64 ≤0.03 32 73 0 27
K. pneumoniae Cefotaxime ≤0.03->128 0.5 128 57 27 17
(30) Gentamicin 0.5->128 1 >128 63 0 37
  Amikacin 1->128 4 >128 53 13 33
  Arbekacin 0.5->128 2 >128 50 3 47
  Ciprofloxacin ≤0.03–128 0.06 32 53 0 47
C. freundii Cefotaxime ≤0.03->128 0.25 64 73 0 27
(15) Gentamicin 0.5->128 1 128 80 7 13
  Amikacin 1->128 2 32 87 7 7
  Arbekacin 0.5->128 1 16 80 0 20
  Ciprofloxacin ≤0.03–8 0.12 4 80 7 13
E. cloacae Cefotaxime ≤0.03->128 0.25 128 60 7 33
(15) Gentamicin 0.25->128 0.5 >128 67 0 33
  Amikacin 1->128 2 >128 80 7 13
  Arbekacin 0.5->128 1 >128 67 7 27
  Ciprofloxacin ≤0.03–4 0.5 4 73 0 27
S. marcescens Cefotaxime 0.12->128 0.5 >128 57 0 43
(14) Gentamicin 0.5->128 1 >128 64 0 36
  Amikacin 2->128 4 >128 64 0 36
  Arbekacin 1->128 4 >128 57 0 43
  Ciprofloxacin 0.06–32 0.12 32 64 7 29
A. baumannii Cefotaxime 4->128 16 >128 40 20 40
(15) Gentamicin 0.5->128 2 >128 60 0 40
  Amikacin 0.5->128 8 >128 73 7 20
  Arbekacin 0.5->128 1 >128 60 13 27
  Ciprofloxacin 0.06->128 0.25 128 53 7 40
P. aeruginosa Cefotaxime 8->128 32 >128 3 62 35
(29) Gentamicin 0.5->128 2 >128 59 3 38
  Amikacin 1->128 8 >128 72 14 14
  Arbekacin 0.5–64 2 64 59 10 31
  Ciprofloxacin 0.06->128 0.25 32 69 0 31

* Arbekacin breakpoint was applied as susceptible, ≤4 μg/mL; intermediate, 8 μg/mL; resistant, ≥16 μg/mL.

Abbreviation: MIC, Minimum inhibitory concentration.

TOOLS
Similar articles